Literature DB >> 2990327

In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics.

M J Hornstein, A M Jupeau, M R Scavizzi, A M Philippon, P A Grimont.   

Abstract

The MICs of 21 beta-lactam antibiotics were measured against 126 clinically significant and epidemiologically unrelated Yersinia enterocolitica isolates. The most active antimicrobial agents tested (geometric means of MICs) were ceftriaxone, cefotaxime, ceftizoxime, and cefmenoxime (0.06 to 0.08 micrograms/ml). Mezlocillin (1.36 micrograms/ml) and piperacillin (1.57 micrograms/ml) were the most active penicillins. Aztreonam and imipenem had MICs of 0.44 and 0.24 micrograms/ml. All isolates exhibited some degree of resistance against ampicillin (MICs, greater than or equal to 4 micrograms/ml) and cephalothin (MICs, greater than or equal to 8 micrograms/ml). Cephalosporinase or penicillinase activities were expressed by all isolates. A principal component analysis of MIC data separated the major serotypes (O3, O9, O8, and O5,27). The MCBs of 14 newer beta-lactams were measured against 10 clinical isolates. On the basis of the ratio of MBC to MIC (expressed in dilution factors), a real bactericidal activity was only observed for imipenem (MBC/MIC = 1). For the other newer beta-lactams, the ratios ranged from 4 to 8.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990327      PMCID: PMC180156          DOI: 10.1128/AAC.27.5.806

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  [Multiplicity of beta lactamases: a problem of isoenzymes].

Authors:  R Labia; M Barthélémy; J M Masson
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1976-11-29

2.  Generalized Yersinia enterocolitica infection.

Authors:  A R Rabson; A F Hallett; H J Koornhof
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

3.  Beta-lactamases from Yersinia enterocolitica.

Authors:  G Cornelis; E P Abraham
Journal:  J Gen Microbiol       Date:  1975-04

4.  Bacteremia with and without meningitis due to Yersinia enterocolitica, Edwardsiella tarda, Comamonas terrigena, and Pseudomonas maltophilia.

Authors:  A C Sonnenwirth
Journal:  Ann N Y Acad Sci       Date:  1970-10-30       Impact factor: 5.691

5.  [Human "Yersinia enterocolitica" septicemia. 17 recent cases].

Authors:  H H Mollaret; T Omland; S D Henriksen; P R Baeroe; G Rykner; M Scavizzi
Journal:  Presse Med       Date:  1971-02-13       Impact factor: 1.228

6.  Antimicrobial susceptibilities of Yersinia enterocolitica biotype 4, serotype O:3.

Authors:  S Hammerberg; S Sorger; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

Review 7.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

8.  Yersinia enterocolitica isolates from humans in California, 1968-1975.

Authors:  M L Bissett
Journal:  J Clin Microbiol       Date:  1976-08       Impact factor: 5.948

9.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

10.  Survey on the incidence of Yersinia enterocolitica infection in Canada.

Authors:  S Toma; L Lafleur
Journal:  Appl Microbiol       Date:  1974-09
View more
  11 in total

Review 1.  A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Authors:  Alain Philippon; Patrick Slama; Paul Dény; Roger Labia
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

2.  Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona.

Authors:  G Prats; B Mirelis; T Llovet; C Muñoz; E Miró; F Navarro
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 3.  Yersinia enterocolitica: the charisma continues.

Authors:  E J Bottone
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  Multidimensional analysis for interpreting antibiotic susceptibility data.

Authors:  M R Scavizzi; A Elbhar; J P Fénelon; F D Bronner
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 5.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

6.  In vitro antimicrobial susceptibilities of Yersinia enterocolitica and related species isolated from slaughtered pigs and pork products.

Authors:  J Kwaga; J O Iversen
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

7.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

Authors:  S P Bonacorsi; M R Scavizzi; A Guiyoule; J H Amouroux; E Carniel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection.

Authors:  M R Scavizzi; J M Alonso; A M Philippon; A M Jupeau-Vessieres; A Guiyoule
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

9.  Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection.

Authors:  B C Lemaitre; D A Mazigh; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.

Authors:  R Vanhoof; J M Hubrechts; E Roebben; H J Nyssen; E Nulens; J Leger; N De Schepper
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.